• Sarepta Therapeutics has appointed Michael Severino, M.D., a veteran of AbbVie, Amgen, Merck and most recently Tessera Therapeutics, as its Chief Executive Officer effective July 28, 2026, succeeding Douglas Ingram.
• By combining the CEO role with a seat on Sarepta’s board, Severino’s broad R&D and corporate strategy background could shape how the company prioritizes its gene therapy and RNA-based rare disease programs.
• Next, we’ll explore how bringing former AbbVie president Michael Severino into the CEO and board roles could reshape Sarepta’s investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

Sarepta Therapeutics Investment Narrative Recap

To own Sarepta, you need to believe ELEVIDYS and the broader genetic medicine portfolio can justify the risks around safety, treatment logistics, and concentrated revenue exposure. The appointment of Michael Severino as CEO and board member does not immediately change the near term focus on ELEVIDYS safety data and label evolution, nor the key risk around acute liver injury and potential regulatory or uptake headwinds.

Among recent updates, the launch of ENDEAVOR Cohort 8 to test enhanced immunosuppression with ELEVIDYS feels most connected to this leadership change. Severino’s background in R&D and complex portfolio oversight comes just as Sarepta is running trials to better manage acute liver injury risk, which sits at the center of both the main growth opportunity and the primary safety overhang on the story.

Yet behind the promise of gene therapy progress, there are safety and operational issues that investors should be aware of, especially around...

Sarepta Therapeutics' narrative projects $1.4 billion revenue and $87.3 million earnings by 2029. This implies a 13.3% yearly revenue decline but an earnings increase of about $800.7 million from -$713.4 million today.

Uncover how Sarepta Therapeutics' forecasts yield a $21.65 fair value, a 36% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming earnings could rise toward about US$232.7 million by 2029, yet today’s CEO change and ELEVIDYS safety focus highlight how much views can differ and how those upbeat scenarios around expanded gene therapy adoption might shift as new information comes in.

Explore 5 other fair value estimates on Sarepta Therapeutics - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Sarepta Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Sarepta Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sarepta Therapeutics' overall financial health at a glance.

No Opportunity In Sarepta Therapeutics?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.